PD‐L1 Immune Checkpoint Targeted Photoactivable Liposomes (iTPALs) Prime the Stroma of Pancreatic Tumors and Promote Self‐Delivery

Abstract

AbstractDesmoplasia in pancreatic ductal adenocarcinoma (PDAC) limits the penetration and efficacy of therapies. It has been previously shown that photodynamic priming (PDP) using EGFR targeted photoactivable multi‐inhibitor liposomes remediates desmoplasia in PDAC and doubles overall survival. Here, bifunctional PD‐L1 immune checkpoint targeted photoactivable liposomes (iTPALs) that mediate both PDP and PD‐L1 blockade are presented. iTPALs also improve phototoxicity in PDAC cells and induce immunogenic cell death. PDP using iTPALs reduces collagen density, thereby promoting self‐delivery by 5.4‐fold in collagen hydrogels, and by 2.4‐fold in syngeneic CT1BA5 murine PDAC tumors. PDP also reduces tumor fibroblast content by 39.4%. Importantly, iTPALs also block the PD‐1/PD‐L1 immune checkpoint more efficiently than free α‐PD‐L1 antibodies. Only a single sub‐curative priming dose using iTPALs provides 54.1% tumor growth inhibition and prolongs overall survival in mice by 42.9%. Overall survival directly correlates with the extent of tumor iTPAL self‐delivery following PDP (Pearson's r = 0.670, p = 0.034), while no relationship is found for sham non‐specific IgG constructs activated with light. When applied over multiple cycles, as is typical for immune checkpoint therapy, PDP using iTPALs promises to offer durable tumor growth delay and significant survival benefit in PDAC patients, especially when used to promote self‐delivery of integrated chemo‐immunotherapy regimens.